[1]RAWLA P.Epidemiology of prostate cancer［J］.World J Oncol,2019,10(2)：63-89.
[2]PATEL N,KHOROLSKY C,BENIPAL B.Incidence of pancreatic adenocarcinoma in the United States from 2001 to 2015：A United States cancer statistics analysis of 50 states［J］.Cureus,2018,10(12)：e3796.
[3]MIAH S,ELDRED-EVANS D,SIMMONS LAM,et al.Patient reported outcome measures for transperineal template prostate mapping biopsies in the PICTURE study［J］.J Urol,2018,200(6)：1235-1240.
[4]FIORELLA D,MARENCO JL,MASCAR SJM,et al.Role of PCA3 and SelectMDx in the optimization of active surveillance in prostate cancer［J］.Actas Urol Esp,2021,45(6)：439-446.
[5]RODR GUEZ SVM,GARC A-PERDOMO HA.Diagnostic accuracy of prostate cancer antigen 3(PCA3)prior to first prostate biopsy：A systematic review and meta-analysis［J］.Can Urol Assoc J,2020,14(5)：E214-E219.
[6]GUNELLI R,FRAGALA E,FIORI M.PCA3 in prostate cancer［J］.Methods Mol Biol,2021,2292：105-113.
[7]WANG FB,CHEN R,REN SC,et al.Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy［J］.Asian J Androl,2017,19(2)：238-243.
[8]LOEB S,CATALONA WJ.The prostate health index：a new test for the detection of prostate cancer［J］.Ther Adv Urol,2014,6(2)：74-77.
[9]RUSSO GI,REGIS F,CASTELLI T,et al.A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-kalli krein panel score in predicting overall and high-grade prostate cancer［J］.Clin Genitourin Cancer,2017,15(4)：429-439.
[10]LOEB S,SANDA MG,BROYLES DL,et al.The prostate health index selectively identifies clinically significant prostate cancer［J］.J Urol,2015,193(4)：1163-1169.
[11]BECERRA MF,BHAT A,MOUZANNAR A,et al.Serum and urinary biomarkers for detection and active surveillance of prostate cancer［J］.Curr Opin Urol,2019,29(6)：593-597.
[12]NA R,YE D,QI J,et al.Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2~10 n g/mL and PSA >10 ng/mL：Results from a multicenter study in China［J］.Prostate,2017,77(11)：1221-1229.
[13]CHIU PK,ROOBOL MJ,TEOH JY,et al.Prostate health index(PHI)and prostate-specific antigen(PSA)predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume［J］.Int Urol Nephrol,2016,48(10)：1631-1637.
[14]NANDAKUMAR V,BORNHORST JA,ALGECIRAS-SCHIMNICH A.Evaluation of PHI clinical performance for the detection of prostate cancer in routine clinical practice［J］.Ann Clin Lab Sci,2021,51(1)：3-11.
[15]WYSOCK JS,BECHER E,PERSILY J,et al.Concordance and performance of 4K score and SelectMDx for informing decision to perform prostate biops y and detection of prostate cancer［J］.Urology,2020,141：119-124.
[16]MI C,BAI L,YANG Y,et al.4K score diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 1 0%：A meta-analysis［J］.Urol Oncol,2021,39(6)：366.
[17]PUNNEN S,PAVAN N,PAREKH DJ.Finding the wolf in sheep’s clothing：the 4Kscore is a novel blood test that can accurately identify the risk of aggressive prostate cancer［J］.Rev Urol,2015,17(1)：3-13.
[18]SJOBERG DD,VICKERS AJ,ASSEL M,et al.Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four ka llikrein markers in a large population-based cohort of healthy men［J］.Eur Urol,2018,73(6)：941-948.
[19]SANGUEDOLCE F,CORMIO A,BRUNELLI M,et al.Urine TMPRSS2：ERG fusion transcript as a biomarker for prostate cancer：literature review［J］.Clin Genitourin Cancer,2016,14(2)：117-121.
[20]LEYTEN GH,HESSELS D,JANNINK SA,et al.Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer［J］.Eur Urol,2014,65(3)：534-542.
[21]GERKE JS,ORTH MF,TOLKACH Y,et al.Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma［J］.Int J Cancer,2020,146(7)：2036-2046.
[22]GOPALAN A,LEVERSHA MA,SATAGOPAN JM,et al.TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy［J］.Cancer Res,2009,69(4)：1400-1406.
[23]TOMLINS SA,DAY JR,LONIGRO RJ,et al.Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment［J］.Eur Urol,2016,70(1)：45-53.
[24]SANDA MG,FENG Z,HOWARD DH,et al.Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive pro state cancer［J］.JAMA Oncol,2017,3(8)：1085-1093.
[25]LEYTEN GH,HESSELS D,SMIT FP,et al.Identification of a candidate gene panel for the early diagnosis of prostate cancer［J］.Clin Cancer Res,2015,21(13)：3061-3070.
[26]VAN NESTE L,HENDRIKS RJ,DIJKSTRA S,et al.Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score［J］.Eur Urol,2016,70(5)：740-748.
[27]KRETSCHMER A,TILKI D.Biomarkers in prostate cancer-current clinical utility and future perspectives［J］.Crit Rev Oncol Hematol,2017,120：180-193.
[28]GOVERS TM,HESSELS D,VLAEMINCK-GUILLEM V,et al.Cost-effectiveness of SelectMDx for prostate cancer in four European countries：a comparative modelin g study［J］.Prostate Cancer Prostatic Dis,2019,22(1)：101-109.
[29]WATERHOUSE RL,VAN NESTE L,MOSES KA,et al.Evaluation of an Epigenetic assay for predicting repeat prostate biopsy outcome in african american men［J］.Urology,2019,128：62-65.
[30]TZELEPI V,LOGOTHETI S,EFSTATHIOU E,et al.Epigenetics and prostate cancer：defining the timing of DNA methyltransferase deregulation during pro state cancer progression［J］.Pathology,2020,52(2)：218-227.
[31]ANCESCHI U,TUDERTI G,LUGNANI F,et al.Novel diagnostic biomarkers of prostate cancer：an update［J］.Curr Med Chem,2019,26(6)：1045-1058.
[32]VAN SLOUN RJG,SOLOMON O,BRUCE M,et al.Super-resolution ultrasound localization microscopy through deep learning［J］.IEEE Trans Med Imaging,2021,40(3)：829-839.
[33]HIRAI T.Expectations for contrast-enhanced ultrasonography［J］.J Med Ultrason(2001),2014,41(1)：1-2.
[34]LI Y,TANG J,FEI X,et al.Diagnostic performance of contrast enhanced ultrasound in patients with prostate cancer：a meta-analysis［J］.Acad Radiol,2013,20(2)：156-164.
[35]CHEN FK,DE CASTRO ABREU AL,PALMER SL.Utility of ultrasound in the diagnosis,treatment,and follow-up of prostate cancer：state of the art［J］.J Nucl Med,2016,57(3)：13-18.
[36]ABOUMARZOUK OM,OGSTON S,HUANG Z,et al.Diagnostic accuracy of transrectal elastosonography(TRES)imaging for the diagnosis of prostate canc er：a systematic review and meta-analysis［J］.BJU Int,2012,110(10)：1414-1423.
[37]ZHANG B,MA X,ZHAN W,et al.Real-time elastography in the diagnosis of patients suspected of having prostate cancer：a meta-analy sis［J］.Ultrasound Med Biol,2014,40(7)：1400-1407.
[38]SIMMONS LAM,KANTHABALAN A,ARYA M,et al.The PICTURE study：diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy［J］.Br J Cancer,2017,116(9)：1159-1165.
[39]SIEGEL C.Transition zone prostate cancer：revisiting the role of multiparametric MRI at 3T［J］.J Urol,2015,194(1)：116.
[40]JUNG SI,DONATI OF,VARGAS HA,et al.Transition zone prostate cancer：incremental value of diffusion-weighted endorectal MR imaging in tum or detection and assessment of aggressiveness［J］.Radiology,2013,269(2)：493-503.
[41]MENG X,ROSENKRANTZ A B,MENDHIRATTA N,et al.Relationship between prebiopsy multiparametric magnetic resonance imaging(MRI),biopsy indication,and MRI-ultrasound fusion-targeted prostate biopsy outcomes［J］.Eur Urol,2016,69(3)：512-517.
[42]KASIVISVANATHAN V,RANNIKKO AS,BORGHI M,et al.MRI-targeted or standard biopsy for prostate-cancer diagnosis［J］.N Engl J Med,2018,378(19)：1767-1777.
[43]AHMED HU,EL-SHATER BOSAILY A,BROWN LC,et al.Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS)：a paired val idating confirmatory study［J］.Lancet,2017,389(10071)：815-822.
[44]TURKBEY B,ROSENKRANTZ AB,HAIDER MA,et al.Prostate imaging reporting and data system version 2.1：2019 update of prostate imaging reporting and data system version 2［J］.Eur Urol,2019,76(3)：340-351.
[45]KHOO CC,ELDRED-EVANS D,PETERS M,et al.Likert vs PI-RADS v2：a comparison of two radiological scoring systems for detection of clinically significant prostate cancer［J］.BJU Int,2020,125(1)：49-55.
[46]GOMEZ GOMEZ E,SALAMANCA BUSTOS JJ,CARRASCO VALIENTE J,et al.Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculator s for the prediction of significant prostate cancer in patients with PSA <10 ng/mL［J］.BMJ Open,2019,9(11)：e031032.
[47]ANKERST DP,HOEFLER J,BOCK S,et al.Prostate cancer prevention trial risk calculator 2.0 for the prediction of low-vs high-grade prostate cancer［J］.Urology,2014,83(6)：1362-1367.
[48]YU W,ZHOU L.Early diagnosis of prostate cancer from the perspective of Chinese physicians［J］.J Cancer,2020,11(11)：3264-3673.
[49]POYET C,NIEBOER D,BHINDI B,et al.Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer(ERSPC)and Prostate Cancer Prevention Trial(PCPT)risk calculators：independ ent validation and comparison in a contemporary European cohort［J］.BJU Int,2016,117(3)：401-408.
[50]FOLEY RW,MAWENI RM,GORMAN L,et al.European Randomised Study of Screening for Prostate Cancer(ERSPC)risk calculators significantly out perform the Prostate Cancer Prevention Trial(PCPT)2.0 in the prediction of prostate cancer：a multi-institutional study［J］.BJU Int,2016,118(5)：706-713.
[51]WU YS,FU XJ,NA R,et al.PHI-based risk calculators performed better in the prediction of prostate cancer in the Chinese population［J］.Asian J Androl,2019,21(6)：592-597.
[52]WEI JT,FENG Z,PARTIN AW,et al.Can urinary PCA3 supplement PSA in the early detection of prostate cancer［J］.J Clin Oncol,2014,32(36)：4066-4072.
[53]WANG Q,LI YF,JIANG J,et al.The establishment and evaluation of a new model for the prediction of prostate cancer［J］.Medicine(Baltimore),2017,96(11)：e6138.
[54]ALBERTS AR,ROOBOL MJ,VERBEEK JFM,et al.Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging：improv ing the rotterdam european randomized study of screening for prostate cancer risk calculators［J］.Eur Urol,2019,75(2)：310-318.
[55]ZHU Y,WANG JY,SHEN YJ,et al.External validation of the prostate cancer prevention trial and the european randomized study of scre ening for prostate cancer risk calculators in a Chinese cohort［J］.Asian J Androl,2012,14(5)：738-744.
[56]CAO DL,YE DW,ZHANG HL,et al.A multiplex model of combining gene-based,protein-based,and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer［J］.Prostate,2011,71(7)：700-710.
[57]ZHU Y,HAN CT,ZHANG GM,et al.Development and external validation of a prostate health index-based nomogram for predicting prostate cancer［J］.Sci Rep,2015,5：15341.
[58]WU YS,ZHANG N,LIU SH,et al.The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population：a training study followed by a validation study［J］.Asian J Androl,2016,18(6)：925-929.